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Atherogenic LOX-1 signaling is controlled by
SPPL2-mediated intramembrane proteolysis
Torben Mentrup1,2, Kosta Theodorou3, Florencia Cabrera-Cabrera1,2, Andreas O. Helbig4, Kathrin Happ2, Marion Gijbels3,5,6, Ann-Christine Gradtke1,2,
Björn Rabe2, Akio Fukumori7, Harald Steiner7,8, Andreas Tholey4, Regina Fluhrer7,8, Marjo Donners3, and Bernd Schröder1,2
The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. LOX-1 promotes
endothelial activation and dysfunction by mediating uptake of oxidized LDL and inducing pro-atherogenic signaling. However,
little is known about modulators of LOX-1–mediated responses. Here, we show that the function of LOX-1 is controlled
proteolytically. Ectodomain shedding by the metalloprotease ADAM10 and lysosomal degradation generate membrane-bound
N-terminal fragments (NTFs), which we identified as novel substrates of the intramembrane proteases signal peptide
peptidase–like 2a and b (SPPL2a/b). SPPL2a/b control cellular LOX-1 NTF levels which, following self-association via their
transmembrane domain, can activate MAP kinases in a ligand-independent manner. This leads to an up-regulation of several
pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tissue growth factor CTGF. Consequently,
SPPL2a/b-deficient mice, which accumulate LOX-1 NTFs, develop larger and more advanced atherosclerotic plaques than
controls. This identifies intramembrane proteolysis by SPPL2a/b as a novel atheroprotective mechanism via negative
regulation of LOX-1 signaling.
Introduction
Atherosclerosis and its clinical manifestations represent a
leading cause of morbidity and mortality (Herrington et al.,
2016). Vascular lesions called atherosclerotic plaques are hall-
marks of the disease. Activation and dysfunction of endothelial
cells and subendothelial accumulation of oxidized low-density
lipoprotein (oxLDL; Steinberg et al., 1989; Di Pietro et al., 2016;
Gimbrone and Garćıa-Cardeña, 2016) are initiating events for
plaque formation (Gimbrone and Garćıa-Cardeña, 2016) by
triggering immune cell recruitment. oxLDL activates endothelial
cells via the lectin-like oxLDL receptor 1 (LOX-1; Sawamura et al.,
1997). LOX-1 is a type II transmembrane protein that belongs
to the family of C-type lectin receptors (Plato et al., 2013; Xu
et al., 2013). The critical role of LOX-1 in atherosclerosis is well
documented by in vivo studies in mice. Constitutive deletion or
endothelial overexpression of LOX-1 attenuated or exacerbated
the development of atherosclerotic plaques (Mehta et al., 2007;
White et al., 2011; Akhmedov et al., 2014), establishing a pro-
atherogenic function of this protein. This is supported by a
significant up-regulation of LOX-1 in human atherosclerotic
lesions (Kataoka et al., 1999).
In addition to oxLDL uptake, LOX-1 triggers signaling path-
ways including the activation of mitogen-activated protein
(MAP) kinases (Li and Mehta, 2000) and the NFκB pathway
(Cominacini et al., 2000;Matsunaga et al., 2003). By this means,
LOX-1 induces expression of adhesion molecules and pro-
inflammatory cytokines and promotes atherogenesis (Li et al.,
2003; Chen et al., 2005; Mattaliano et al., 2009; Thakkar et al.,
2015). Molecular factors regulating LOX-1 stability and signaling
functions remain poorly defined. Proteolytic cleavage of LOX-1 lib-
erates a soluble form of this receptor (sLOX-1; Murase et al., 2000).
Serum levels of sLOX-1 are modulated in cardiovascular disease
(Hayashida et al., 2005). However, the proteolytic enzymes re-
sponsible for this have remained controversial (Murase et al., 2000;
Mitsuoka et al., 2009; Zhao et al., 2011). Furthermore, the function
of the individual cleavage fragments and the impact of prote-
olysis on LOX-1 signaling are undefined to date.
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Proteolysis of transmembrane proteins is a well-established
mechanism to control their abundance and function (Lichtenthaler
et al., 2011). In a sequential process, referred to as regulated in-
tramembrane proteolysis, a cleavage within the substrate’s ecto-
domain is followed by the action of an intramembrane-cleaving
protease (I-CLIP) processing the residual membrane-embedded
stub. The resulting intracellular domain (ICD) is released into the
cytosol and can fulfil regulatory functions like in Notch signal
transduction (De Strooper et al., 1999).
Signal peptide peptidase–like 2a and b (SPPL2a, SPPL2b) are
I-CLIPs functioning in such regulated intramembrane proteol-
ysis sequences (Voss et al., 2013) by cleaving N-terminal frag-
ments (NTFs) derived from type II transmembrane proteins.
They are GxGD-type aspartyl I-CLIPs with homology to pre-
senilins (Voss et al., 2013). SPPL2a and SPPL2b exhibit divergent
subcellular localizations in lysosomes/late endosomes and at the
plasma membrane (Friedmann et al., 2006; Behnke et al., 2011;
Schneppenheim et al., 2014b). While most substrates identified
to date have been analyzed in cell-based systems, in vivo rele-
vance was shown for SPPL2a-mediated cleavage of the invariant
chain (CD74) of the MHCII complex, which is an essential pro-
cess in development of B cells and dendritic cells documented by
a deficiency of these cell types in SPPL2a-deficient mice (Beisner
et al., 2013; Bergmann et al., 2013; Schneppenheim et al., 2013).
In contrast, the in vivo function of SPPL2b is less clear, and
evidence for SPPL2b substrates under endogenous conditions is
still lacking.
Here, we show that proteolytic pathways regulate the sig-
naling function of LOX-1. Lysosomal proteolysis and ectodomain
shedding contribute to the generation of membrane-bound LOX-1
NTFs, which are capable of inducing ligand-independent pro-
atherogenic and pro-fibrotic signaling. We demonstrate that
levels of the LOX-1 NTFs are controlled by SPPL2a/b, accounting
for enhanced LOX-1 signaling in the absence of these pro-
teases. Concomitantly, mice with SPPL2a/b deficiency in non-
hematopoietic cells are more susceptible to the development
of atherosclerotic plaques. Therefore, we identify SPPL2a/b as
essential negative regulators of LOX-1 signaling as well as of
atherosclerosis.
Results
LOX-1 is processed by ADAM10 and lysosomal proteases
Based on the described soluble form of LOX-1, we investigated
proteolytic processing of this protein in more detail. When we
expressed N-terminally HA (hemagglutinin) epitope–tagged
murine LOX-1 in HeLa (Fig. 1 A) or immortalized murine aortic
endothelial cells (iMAECs; Fig. 1 B), we observed the full-length
LOX-1 protein (FL) as well as two hitherto unknown fragments
of ∼25 and 17 kD, which we termed NTF1 and NTF2. Based on the
potential glycosylation of NTF1 suggested by its diffuse band, the
two N-glycosylation sites N72 and N92 in the stalk domain
(Fig. S1 A) were substituted by alanines (Fig. 1 C). Mutation of
N72 led to a shift of NTF1, but not of NTF2, indicating that
NTF2 does not contain N72. In contrast, blocking glycosylation
at N92 did not alter the migration of any of the NTFs, affect-
ing, however, that of the LOX-1 full-length protein. This
indicates that NTF1 and NTF2 represent distinct proteolytic
fragments. Whereas NTF1 is generated by proteolysis between
N72 and N92, the cleavage leading to NTF2 has to occur
N-terminally to N72.
With regard to previous reports (Mitsuoka et al., 2009; Zhao
et al., 2011), we assessed the role of ADAM proteases in LOX-1
processing using HEK cells deficient for ADAM10 and/or
ADAM17 (Fig. 1, D and E). The release of sLOX-1 was completely
abolished in cells lacking ADAM10, while absence of ADAM17
had no influence on this process. In line, the production of sLOX-1
in iMAECs was stimulated by ionomycin, an ADAM10 activa-
tor, but not by PMA, which stimulates ADAM17 (Fig. 1 F). Even in
ADAM10 KO cells, no LOX-1 shedding upon PMA treatment was
observed (Fig. S1 B). Unexpectedly, the abolished shedding only
led to a minor reduction of both NTFs (Fig. 1, D–F) arguing for
additional proteolytic pathways for NTF generation. To define
these, we tested a panel of protease inhibitors. Bafilomycin a1, an
inhibitor of lysosomal acidification, significantly reduced levels
of both NTFs (Fig. 1, G and H; and Fig. S1 C). This pointed to a role
of pH-dependent lysosomal proteases in LOX-1 processing. In
agreement, we observed a partial colocalization of overex-
pressed LOX-1 with the lysosomal protein LAMP-2 (Fig. 1 I).
Furthermore, the cysteine protease inhibitor E-64d caused a
reduction of NTF2 (Fig. S1 C). Interestingly, in this case NTF1
was not depleted, but rather stabilized. Thus, multiple lyso-
somal proteases are involved in the generation of NTF1 and
NTF2. Importantly, NTF-production was not influenced by the
LOX-1 ligand oxLDL (Fig. 1, K and L), arguing for a constitutive
internalization of the receptor followed by proteolytic deg-
radation in lysosomal compartments. Conversely, inhibiting
LOX-1 processing influenced neither oxLDL uptake (Fig. S1 D)
nor LOX-1 surface levels (Fig. S1 E).
LOX-1 NTFs undergo intramembrane cleavage by SPPL2a/b
We hypothesized that the LOX-1 NTFs are further processed by
intramembrane proteases. Based on their topology and locali-
zation, we considered SPPL2a and SPPL2b as candidate I-CLIPs.
Co-expression of LOX-1 with either protease, but not their cat-
alytically inactive mutants led to a significant reduction of both
NTFs that could be blocked with the SPP/SPPL inhibitor (Z-LL)2-
ketone (ZLL; Fig. 2 A). However, NTF depletion induced by
SPPL2b was more pronounced (Fig. 2 B). Upon SPPL2a/b coex-
pression with LOX-1, a smaller band presumably representing
the released LOX-1 ICD was enhanced. Immunofluorescence
analysis confirmed overlapping distributions between the sub-
strate and both proteases (Fig. 2 C).
We investigated if LOX-1 NTFs are also substrates of endog-
enous SPPL2a/b proteases. In LOX-1 expressing iMAECs, ZLL
stabilized both LOX-1 NTFs (Fig. 2, D and E). Similarly, when
analyzing LOX-1 processing in WT and SPPL2a/b double-
deficient (dKO) MEF cells, levels of both NTFs were signifi-
cantly higher in the KO cells (Fig. 2, F and G). We aimed to de-
lineate the individual contributions of SPPL2a and SPPL2b and
included SPPL2a and SPPL2b single-deficient MEF cells. Though
a minor increase of the LOX-1 NTF1 was observed in SPPL2b−/−
MEFs, only the combined ablation of SPPL2a and SPPL2b led to
the described major stabilization of LOX-1 NTF2, arguing for a
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Figure 1. LOX-1 NTFs are generated by ADAM10 and lysosomal proteases. (A and B) Two LOX-1 NTFs were detected by Western blotting upon
overexpression of HA-LOX-1 in either HeLa (A) or iMAEC (B) cells. (C) Usage of the potential glycosylation sites at N72 or N92 was analyzed in HeLa cells using
respective mutants. (D) HEK cells deficient for ADAM10, ADAM17, or both and WT cells were transfected with HA-LOX-1-FLAG. sLOX-1 was recovered from
conditioned media after 16 h by TCA precipitation. (E) Quantification of D. N = 2–3, n = 4–6. One-way ANOVA with Dunnett’s post hoc test. (F) iMAECs stably
expressing HA-LOX-1-FLAG were preincubated for 2 h in serum-free DMEM containing 10 µM marimastat (Mari) or DMSO. Cells were treated for 30 min with
1 µM ionomycin (Iono) or 100 nM PMA. Cell lysates and conditioned media were analyzed as in D. (G) Lysosomal processing of HA-LOX-1 was blocked in HeLa
cells by incubation with 100 nM bafilomycin a1 (Baf a1) for 24 h. (H) Quantification of G. N = 3, n = 3. Student’s t test. (I) Delivery of HA-LOX-1 to LAMP-2–
positive compartments was visualized by indirect immunofluorescence in HeLa cells treated with either DMSO or 100 nM bafilomycin a1 for 6 h. Bars, 10 µm.
(K) HA-LOX-1–expressing HeLa cells were treated for 4 h with 40 or 80 µg/ml oxLDL, and NTF formation was analyzed by Western blotting. (L) Quantification
of NTF1+2/FL ratios of cells treated with 40 µg/ml oxLDL. N = 2, n = 4. Student’s t test. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not significant. N, the number
of independent experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
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synergistic role of endogenous SPPL2a/b in LOX-1 processing
(Fig. 2, H and I).
We wanted to confirm that the effect of SPPL2a/b on LOX-1
NTFs represents proteolysis within the transmembrane domain
(TMD). Therefore, we expressed a LOX-1 model NTF (Fig. 3 A)
comprising amino acids 1–88 together with SPPL2a or SPPL2b
in HEK cells and recovered the C-terminal cleavage products
for mass-spectrometric analysis from the media. To avoid
heterogeneity by N-glycosylation, wemutated the N-glycosylation
site at N72. We observed six specific cleavage fragments
(Fig. 3 B) that were not present in control samples (Fig. S1 F).
The determined peaks were matched with theoretical masses
calculated for C-terminal peptides based on the NTF sequence
(Fig. 3 C). Both proteases exhibited multiple overlapping cleav-
age sites within the TMD of LOX-1. Interestingly, SPPL2a
showed a strong preference for proteolysis N-terminal to
L52, whereas the predominant site used by SPPL2b was
shifted to I53.
Figure 2. LOX-1 NTFs undergo SPPL2a/b-dependent intramembrane proteolysis. (A) HeLa cells were transfected with HA-LOX-1 and WT or inactive
(D/A) SPPL2 proteases. Where indicated, SPPL2a/b activity was inhibited with 20 µM ZLL for 6 h. (B) Quantification of A. N = 7, n = 7. Student’s t test. Norm.,
normalized. (C) Colocalization of HA-LOX-1 and SPPL2a-myc or SPPL2b-myc in transfected HeLa cells. (D and E) iMAECs transfected with HA-LOX-1 were
treated with 40 µM ZLL for 24 h before Western blot analysis. LOX-1 (NTF1+2)/FL ratios are depicted in E. N = 2, n = 5. Student’s t test. (F and G) WT or
SPPL2a/b dKOMEFs were stably transduced with HA-LOX-1-FLAG followed by Western blot analysis. LOX-1 (NTF1+2)/FL ratios are depicted in G. N = 2, n = 6.
Student’s t test. (H)WT, SPPL2a- SPPL2b-, or double-deficient MEFs were transfected with HA-LOX-1 and analyzed by Western blotting. (I) Quantification of
H. N = 3–4, n = 5–8. One-way ANOVA with Tukey’s post hoc testing. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not significant. N, the number of independent
experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
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Figure 3. The LOX-1 TMD is important for SPPL2-dependent intramembrane cleavage. (A–C) Mass-spectrometric determination of SPPL2a/b cleavage
sites within the LOX-1 NTF. (A) Amino acid sequence of the employed model substrate. Determined cleavage sites in the TMD (gray) are marked. (B) Secreted
C-terminal fragments were purified from conditioned media and analyzed by MS. Arrows indicate peptides increased by protease overexpression with the
predominant peaks labeled in red. (C) Peptides assigned to the respective peaks shown in B. Peak 5 corresponds to a peptide with a potential N-terminal
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We aimed to identify determinants within the LOX-1 TMD
required for the intramembrane cleavage. Based on the role of
helix destabilization for intramembrane proteolysis (Langosch
et al., 2015), we tried to increase the stability of the LOX-1 TMD
by replacing either selected polar or helix-destabilizing residues
(TMDstab) or blocks of amino acids (32–36I, 37–42I, 43–48I,
49–54I) with isoleucines (Fig. 3 D). All mutants reached the
plasma membrane like the LOX-1 WT NTF (Fig. 3 E). Whereas
processing of most mutants by coexpressed SPPL2b was not
compromized, exchange of residues 43–48 significantly im-
paired intramembrane cleavage (Fig. 3, F and G). Interestingly, the
residues surrounding the cleavage sites between T51, L52, and I53
could be replaced without a significant loss of cleavability.
Endogenous LOX-1 is a substrate of SPPL2a and SPPL2b
To analyze endogenous LOX-1, we generated an antiserum
against an N-terminal epitope (aa 2–19) of the protein (Fig. 4, A
and B). We confirmed endogenous expression of SPPL2a and
SPPL2b in iMAECs and aortic lysates (Fig. 4 C) and observed that
inhibition of SPP/SPPL proteases stabilized endogenous LOX-1
NTF2 in iMAECs (Fig. 4, D and E). We also analyzed LOX-1 pro-
cessing in aortae isolated from WT as well as SPPL2a/b single-
and double-deficient mice (Fig. 4, F and G). Similar to iMAECs,
we exclusively detected NTF2 in these samples. Only minor
amounts of LOX-1 NTF2 were detected in WT aortae, whereas
those from dKO mice exhibited a major accumulation. In both
the single-deficient aortae, NTF2 abundance was increased.
However, levels were much lower than in the dKO aortae,
strongly highlighting the importance of both proteases for
LOX-1 processing in vivo.
Inhibition of SPPL2a/b enhances ligand-dependent
LOX-1–induced MAP kinase signaling
We assessed the impact of SPPL2a/b-mediated LOX-1 proteolysis
on the signaling of this receptor. Therefore, we generated an
inducible LOX-1–expressing HEK cell line (Fig. 5 A). Treatment
with oxLDL triggered phosphorylation of the MAP kinases
ERK1/2 (pERK) only when LOX-1 expression was induced (Fig. 5 B).
Importantly, inhibition of SPPL2a/b enhanced ERK activation
(Fig. 5, B and C). This effect was recapitulated in ZLL-treated
glutamate to pyroglutamate conversion. obs., observed; calc., calculated. (D) Scheme of LOX-1 NTF TMD mutants. (E) Subcellular sorting of LOX-1 TMD
mutants was compared with the WT LOX-1 NTF by indirect immunofluorescence with anti-HA in HeLa cells. Bar, 10 µm. (F) Cleavage of LOX-1 NTF TMD
mutants by SPPL2b was analyzed in transfected HeLa cells. (G) Quantification of F. N = 4, n = 4. One-way ANOVA with Dunnett’s post hoc test. ***, P ≤ 0.001;
ns, not significant. N, the number of independent experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
Figure 4. Endogenous LOX-1 is processed by SPPL2a and SPPL2b. (A and B) Evaluation of functionality of the newly generated antibody against the N
terminus of murine LOX-1 in transfected HeLa cells. (A) Blot probed with new antibody. (B) Same blot as in A probed with anti-HA. (C) Expression of SPPL2a
and SPPL2b was demonstrated in iMAECs and aortic lysates by Western blotting. (D) iMAECs were treated for 24 h with either 40 µM ZLL or DMSO before
Western blot analysis. (E)Quantification of D. N = 2, n = 6. Student’s t test. (F) LOX-1 NTF levels were analyzed in aortic lysates fromWT, SPPL2a-, SPPL2b-, or
dKO mice by Western blotting. (G) Quantification of F. N = 4, n = 4. One-way ANOVA with Tukey’s post hoc testing. **, P ≤ 0.01; ns, not significant. N, the
number of independent experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
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Figure 5. The LOX-1 NTF regulates MAP kinase activity. (A) T-REx FlipIn cells inducibly overexpressing LOX-1 were generated. LOX-1 expression after
induction with 10 µg/ml doxycycline (dox) for 24 h was confirmed by Western blotting. (B) LOX-1 expression was induced in T-REx FlipIn cells (+dox) or cells
were left uninduced (–dox). Prior to stimulation with 40 µg/ml oxLDL, cells were cultured in serum-free DMEM for 4 h in the presence of 40 µM ZLL or DMSO.
pERK and total ERK1/2 (ERK) levels were determined. (C) Quantification of B. N = 4, n = 4. Student’s t test. (D) iMAECs were incubated with 40 µM ZLL or
DMSO for 24 h. For the last 4 h, cells were transferred to serum-free DMEM before treatment with 40 µg/ml oxLDL and analysis of ERK1/2 activation.
(E) Quantification of D. N = 4, n = 4. Student’s t test. (F) LOX-1 surface levels were analyzed by flow cytometry in iMAECs stably overexpressing LOX-1 after
24 h treatment with 40 µM ZLL. N = 2, n = 6. Student’s t test. (G) Stable expression of the LOX-1 NTF in transduced iMAECs was validated. (H) Transduced
iMAECs were cultivated for 4 h under serum-free conditions before stimulation with 40 µg/ml oxLDL and assessment of MAP kinase activation. (I) Quan-
tification of H. N = 3, n = 3. Student’s t test. (K) HeLa cells were transfected as indicated with differentially tagged full-length LOX-1 and NTF. Interaction of
both proteins was analyzed by coimmunoprecipitation using anti-V5. (L) HeLa cells transfected with 3xFLAG-LOX-1 (3xFLAG-FL) and/or HA-LOX-11-88
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iMAECs (Fig. 5, D and E). Based on endogenous LOX-1 ex-
pression in this cell type, this substantiates that SPPL2a/b
negatively regulate LOX-1 signaling. We hypothesized that
enhanced LOX-1 signaling upon SPPL2a/b inhibition could be
caused by increased presence of LOX-1 at the cell surface.
Since we failed to detect endogenous LOX-1 in iMAECs by flow
cytometry, we quantified LOX-1 surface levels in iMAECs
overexpressing LOX-1 upon treatment with ZLL, which were
not changed compared with controls (Fig. 5 F).
Since SPPL2a/b inhibition or deficiency induces accumula-
tion of LOX-1 NTFs (Fig. 4, D–G), we considered a direct role of
these fragments in enhancing LOX-1 signaling. Therefore, we
stably expressed an untagged LOX-1 NTF in iMAECs (Fig. 5 G)
and compared ERK phosphorylation in response to oxLDL to
control cells (Fig. 5 H). In NTF-expressing cells, oxLDL-induced
ERK activation was strongly augmented (Fig. 5 I) pheno-copying
SPPL2a/b inhibition (Fig. 5, D and E). We postulated a molecular
interaction between this fragment and full-length LOX-1, which
was confirmed by coimmunoprecipitation in transfected HeLa
cells (Fig. 5 K). LOX-1 can form oligomers depending on receptor
density (Matsunaga et al., 2007). Oligomerization was found to
positively correlate with ligand binding. We evaluated if presence
of theNTF increases LOX-1 oligomerswhich can be cross-linked in
HeLa cells expressing LOX-1 full-length and/or the NTF. Despite
minor changes in the band pattern, the overall amount of LOX-1
full-length oligomers was not considerably modulated by the NTF
(Fig. 5 L), questioning the relevance of the described NTF–full-
length LOX-1 interaction for the enhanced signaling.
The LOX-1 NTF activates MAP kinases independent of
LOX-1 ligands
We noticed that in NTF-expressing iMAECs ERK activation was
already significantly increased before the addition of oxLDL
(Fig. 5, H and I). We analyzed further signaling pathways in
unstimulated iMAECs overexpressing the LOX-1 NTF (Fig. 6,
A–C). In addition to ERK, activation of p38 MAP kinase was
significantly enhanced. In contrast, we did not detect increased
phosphorylation of the NFκB subunit p65 or the kinase AKT.
Thus, the LOX-1 NTF triggers a specific ligand-independentMAP
kinase activation. To validate the ligand independence, we re-
analyzed NTF-expressing iMAEC and control cells after serum
deprivation. Increased levels of pERK and p38 were preserved
under these conditions (Fig. 6, D and E). We repeated these
experiments in HEK cells. Like in iMAECs, expression of the
LOX-1 NTF significantly increased basal activation of ERK and
p38. No effects on Akt and p65 were observed (Fig. 6, F and G).
In HEK cells, endogenous LOX-1 expression was in the range
of the detection limit of the performed quantitative RT-PCR
(qRT-PCR; data not shown). Therefore, MAP kinase activation
by the LOX-1 NTF can be considered independent of the full-
length receptor.
Several upstream pathways are involved in LOX-1 NTF induced
MAP kinase activation
We aimed to delineate the pathways triggered by the LOX-1 NTF
responsible for MAP kinase activation in iMAECs (Fig. 6, H–L).
Inhibition of MEK1/2 by U0126 potently reduced activation of
ERK, however, had no significant impact on p38. In addition, we
also assessed inhibitors against Src family as well as Rho-
associated protein kinases (ROCKs). Whereas inhibition of Src
kinases impaired activation of both ERK and p38, ROCK inhi-
bition only affected the latter. Thus, not a single, but multiple
upstream pathwaysmediateMAP kinase activation by the LOX-1
NTF. We aimed to identify the molecular determinants within
the LOX-1 NTF required for the signaling activation.Wemutated
all phosphorylatable residues within the cytoplasmic domain of
the NTF (Fig. 6 M). However, this mutant was not compromised
with regard to MAP kinase activation (Fig. 6, N and O). Fur-
thermore, we evaluated the signaling potential of the isoleucine
transmembrane mutants. Surprisingly, their capability to in-
duce signaling was significantly reduced (Fig. 6, P and Q),
pointing to a critical role of the TMD, which could act as inter-
action interface. Based on the described NTF full-length inter-
action, we tested the ability of the LOX-1 NTF for homophilic
interactions. Differentially tagged WT LOX-1 NTFs could be ef-
ficiently coimmunoprecipitated. This interaction was abolished
with any of the four TMD mutants (Fig. 6, R and S), indicating
that the ability of the NTF to undergo homo- and/or heterophilic
protein–protein interactions via the TMD is critical for MAP
kinase activation.
LOX-1 NTF triggered signaling induces pro-atherogenic and
-fibrotic targets
A well-established downstream effect of LOX-1 activation is the
up-regulation of adhesion molecules like ICAM-1 (Chen et al.,
2005; Inoue et al., 2005). Western blotting revealed a significant
increase of ICAM-1 in NTF-overexpressing iMAECs (Fig. 7, A and
B). This was also reflected in higher ICAM-1 levels at the cell
surface (Fig. 7 C) in a similar range as induced by TNF. Impor-
tantly, also Icam1mRNA was increased (Fig. 7 D), indicating that
the LOX-1 NTF acts by enhancing Icam1 expression.
We screened for further targets influenced by NTF over-
expression in the same system using qRT-PCR–based arrays
(Table S1). 11 targets were selected for further validation (Fig. 7,
E and F). We could confirm a significant up-regulation of the
chemokine Cxcl2, the CASP8 and FADD-like apoptosis regulator
Cflar, the connective tissue growth factor Ctgf, the granulocyte-
macrophage colony-stimulating factor Csf2, and the platelet-
derived growth factor subunit B Pdgfb in iMAECs overexpressing
the LOX-1 NTF. In contrast, mRNA levels of the platelet factor
4 Pf4 were significantly reduced. In case of CTGF, we confirmed
enhanced production of this secreted protein by Western blot
analysis of Brefeldin A–treated cells (Fig. 7, G and H).
(HA-NTF) were treated for 30 min with BS3 and subsequently analyzed by Western blotting. As described in Materials and methods, phosphorylated and total
forms of ERK were detected from the same membranes. After detection of pERK, the respective membranes were stripped and reprobed to detect total ERK.
***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not significant. N, the number of independent experiments; n, the number of individual samples for quantification. All
data are shown as mean ± SD.
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We assessed the relevance of the described signaling path-
ways for the identified transcriptional regulation. Therefore, we
determined the effect of MEK, Src, and ROCK inhibition on the
up-regulation of Icam1 (Fig. 7 I), Pdgfb (Fig. 7 K), and Ctgf (Fig. 7 L).
Whereas ROCK inhibition significantly counteracted the increase
of Icam1 expression, none of the other compounds had significant
effects on this target. In contrast, Src inhibition effectively reduced
mRNA levels of Pdgfb and Ctgf. In addition, the NTF-associated Ctgf
up-regulationwas also responsive toMEK inhibition. Thus, several
upstream pathways in individual combinations contribute to the
transcriptional effects, highlighting the complexity of the LOX-1
NTF-induced signaling.
Next, wewondered if also an NTF accumulation derived from
inhibiting the intramembrane cleavage of endogenous LOX-1
would impact on the identified target genes. Therefore, mRNA
levels of the validated targets were determined in ZLL-treated
iMAECs and controls. With the exception of Cflar and Pf4, we
observed a significant up-regulation of Icam1, Pdgfb, Csf2, Ctgf,
and Cxcl2 upon SPPL2a/b inhibition (Fig. 7 M). We also analyzed
ICAM-1 surface levels by flow cytometry and found a significant
increase in inhibitor-treated cells (Fig. 7 N). This further confirms
that in iMAECs, SPPL2a/b inhibition phenocopies overexpression
of the LOX-1 NTF. These findings strongly suggest that SPPL2a/b
deficiency induces a pro-atherogenic and pro-fibrotic state in
endothelial cells via the accumulation of LOX-1 NTFs.
Enhanced atherosclerosis in SPPL2a/b double-deficient mice
In healthy aortae fromWTmice, low levels of the LOX-1 NTF are
present (Fig. 4 F), which are increased following induction of
atherosclerosis (Fig. S2, A and B). This suggests a need for
SPPL2a/b to clear this fragment under such conditions.
Therefore, we analyzed if SPPL2a/b deficiency has an impact
on the development of atherosclerosis in vivo. We wanted
to exclude that the immunological phenotype of SPPL2a/b-
deficient (dKO) mice (Schneppenheim et al., 2014b) caused by
defective processing of CD74 (Schneppenheim et al., 2013)
confounds the analysis. Therefore, dKO and WT mice were
reconstituted with WT bone marrow (Fig. S2 C), and recovery
of normal hematopoiesis was confirmed by flow-cytometric
analysis of blood samples (Fig. S2, D and E). At the end of
the experiment, analysis of splenocytes demonstrated a full
correction of the B cell maturation block of the dKO mice
(Fig. 8 A and Fig. S2 F).
After recovery from transplantation, hypercholesterolemia
was induced by adeno-associated viral overexpression of a
PCSK9 gain-of-function mutant in combination with a Western-
type high cholesterol diet (HCD; Bjørklund et al., 2014). This
model has been recently established as an effective approach to
eliminate LDL receptor molecules from the cell surface, thereby
causing hypercholesterolemia comparable to Lldr−/− mice but
circumventing the need for genetic ablation of the correspond-
ing gene (Goettsch et al., 2016; Lu et al., 2016; Rogers et al., 2017;
Theodorou et al., 2017). In agreement with this, mice of both
genotypes developed significant hypercholesterolemia and hy-
pertriglyceridemia (Fig. 8 B). However, plasma cholesterol
concentrations in the treated dKO mice were ∼30% lower than
in control mice. Strikingly, even despite lower plasma choles-
terol levels, atherosclerotic lesion size was significantly in-
creased in the dKO mice (Fig. 8 C). While plaque macrophage
and smooth muscle cell content were not altered between both
genotypes, dKO mice displayed a twofold increase in plaque
collagen (Fig. 8 C). Furthermore, plaques of these mice had
larger necrotic areas than those of controls (Fig. 8 D). Histo-
pathological scoring revealed an increased proportion (52% vs.
36%) of advanced atherosclerotic plaques in dKO animals
(Fig. 8 E), highlighting a pro-atherogenic effect of SPPL2a/b
deficiency in nonhematopoietic cells in vivo.
We analyzed MAP kinase activation in atherosclerotic aortic
arches (Fig. 8 F). In line with the findings in cell-based experi-
ments, phosphorylation of ERK and p38 was significantly en-
hanced in atherosclerotic aortae from dKO mice (Fig. 8 G).
Activation of Akt and NFκB pathways was similar in samples
from both genotypes (Fig. S2 G). In addition, also ICAM-1 was
strongly up-regulated in the aortae from dKO mice after ather-
osclerosis induction (Fig. 8, F and G). Therefore, the cellular
phenotypes linked to SPPL2a/b deficiency and enhanced LOX-1
NTF levels in vitro were recapitulated upon induction of ath-
erosclerosis in vivo.
Despite this obvious correlation, an additional impact of
further substrates to the atherosclerotic phenotype of SPPL2a/b-
deficient mice is in general conceivable. Therefore, we per-
formed Western blot analysis of TNF-activated iMAECs as well
Figure 6. The LOX-1 NTF autonomously activatesMAP kinases. (A and B) iMAECs were stably transduced with the pMSCV puro vector (–) or a LOX-1-NTF
coding construct. Levels of phosphorylated as well as total ERK1/2, p38 (A), p65, and Akt (B) were analyzed by Western blotting. (C) Quantification of A and B.
N = 3, n = 9. Student’s t test. (D) Control or NTF-transduced iMAECs were starved for 16 h in serum-free DMEM and subsequently analyzed for activation of
MAP kinases. (E) Quantification of D. N = 2, n = 6. Student’s t test. (F) Vector (–) or LOX-1 NTF transfected HEK cells were selected with puromycin for 4 d.
(G)Quantification of F. N = 2, n = 7. Student’s t test. (H) Empty vector (–) or LOX-1 NTF transduced iMAECs were treated for 3 h with 25 µM U0126 (MEK-Inh.),
1 µM Saracatinib (Src-Inh.), or 10 µM Y-27632 (ROCK-Inh.) and subsequently analyzed for ERK1/2 activation. (I) Quantification of H. N = 2, n = 6. One-way
ANOVA with Tukey’s post hoc test. (K) Pathways upstream of p38 MAP kinase activation were assessed as depicted in H. (L) Quantification of K. n = 4, n = 12.
One-way ANOVAwith Tukey’s post hoc test. (M) Subcellular sorting of an unphosphorylatable LOX-1 NTF (NTFΔP) was compared with theWTNTF by indirect
immunofluorescence in HeLa cells. Bars, 10 µm. (N) HEK cells were transfected and incubated for 4 d with 10 µg/ml puromycin. Activation of ERK1/2 was
monitored by Western blotting. (O) Quantification of N. pERK/ERK levels were normalized (norm.) to LOX-1 NTF expression. N = 2, n = 6. Student’s t test.
(P) Induction of pERK by LOX-1 TMD mutants was analyzed by Western blotting. (Q) pERK/ERK ratios were normalized to NTF expression. N = 3, n = 6. One-
way ANOVA with Dunnett’s post hoc test. (R) Coimmunoprecipitation of the HA-tagged NTF mutants with a FLAG-tagged WT LOX-1 NTF from lysates of
transfected HEK cells. (S) Quantification from N = 3, n = 3 experiments. One-way ANOVA with Dunnett’s post hoc test. As described in Materials and methods,
phosphorylated and total forms of ERK, p38, p65, and Akt were detected from the same membranes. After detection of the phosphorylated forms, membranes
were stripped and reprobed to detect the total proteins. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not significant. N, the number of independent experiments;
n, the number of individual samples for quantification. All data are shown as mean ± SD.
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Figure 7. Accumulation of the LOX-1 NTF induces a pro-atherogenic state in endothelial cells. (A) Expression of ICAM-1 was analyzed in control (–) or
LOX-1 NTF transduced iMAECs by Western blotting. (B) Quantification of A. N = 2, n = 6. Student’s t test. (C) Up-regulation of surface ICAM-1 in LOX-1 NTF
transduced iMAECs was validated by flow cytometry. As a control, cells were treated with 5 ng/ml TNF. N = 2, n = 6. One-way ANOVA with Tukey’s post hoc
test. (D) Up-regulation of Icam-1was validated by qPCR. N = 2, n = 6. Student’s t test. (E) Candidate genes from endothelial cell biology and atherosclerosis RT2
Profiler arrays with differential regulation between control and iMAEC NTF cells. (F) Differences in mRNA levels of the selected genes were validated by qPCR.
N = 2–3, n = 6–9. Student’s t test. (G) Secretion of CTGF was blocked in iMAEC control (−) or NTF cells by incubation with Brefeldin A (1 µg/ml) for 6 h.
Intracellular CTGF levels were analyzed by Western blotting. (H) Quantification of G. N = 2, n = 12. Student’s t test. (I–L) iMAEC control or NTF cells were
treated for 3 h with 25 µM U0126 (MEK-Inh.), 1 µM Saracatinib (Src-Inh.), or 10 µM Y-27632 (ROCK-Inh.) or left untreated as indicated. Icam-1 (I, N = 3–4, n =
9–12), Ctgf (K, N = 3, n = 8–9), and Pdgfb (L, N = 3, n = 8–9) mRNA levels were quantified by qPCR. One-way ANOVA with Dunnett’s post hoc test. (M) Up-
regulation of validated candidate genes was monitored in iMAECs treated for 16 h with either DMSO or 40 µM ZLL. N = 2–3, n = 6–9. Student’s t test. (N) Up-
regulation of ICAM-1 upon ZLL administration was validated by flow cytometry. N = 3, n = 11. Student’s t test. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not
significant. N, the number of independent experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
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Figure 8. Enhanced atherosclerosis in SPPL2a/b double-deficient mice. (A–G) Hypercholesterolemia and atherosclerosis were induced in WT and
SPPL2a/b-deficient (dKO) mice by adeno-associated viral expression of D377Y-mPCSK9 and an HCD for 9 wk following bone marrow transplantation (BMT)
with WT bone marrow. (A) Proportions of transitional stage 1 (1) and 2 (T) as well as mature B cells (% of viable splenocytes) were analyzed by flow cytometry
at the end of the atherosclerosis experiment. The dot plots depict viable B220+ splenocytes. (B) Plasma triglyceride (TG) and cholesterol (Chol) levels were
determined 3 wk after HCD initiation. N = 2, n = 18–20. (C) Atherosclerotic plaque development was analyzed histologically in H&E-stained aortic root cross-
sections. Bars, 400 µm. Plaque macrophage, smooth muscle cell, and collagen contents were quantified based on MAC3, αSMA (alpha smooth muscle actin),
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as aortae from WT and dKO mice for the best characterized
substrates CD74 and TNF. We failed to detect relevant amounts
of these proteins in these samples (Fig. S3, A–C). In addition, we
performed a quantitative proteomic analysis of aorta from WT
and dKO mice (Fig. S3 D and Table S2). We detected 3 known
SPPL2a/b substrates and 120 other type II transmembrane
proteins as substrate candidates. However, their abundance
was not different between both genotypes. Thus, in these
approaches we did not obtain evidence for other SPPL2a/b
substrates being of pathophysiological importance in en-
dothelial cells and aortae, supporting the critical role of the
LOX-1–SPPL2a/b axis.
SPPL2a/b proteases in human atherosclerosis
With regard to the clinical relevance of atherosclerosis, we de-
termined if the pathway identified in mice also has implications
for atherosclerosis in humans. Thus, we analyzed proteolytic
processing of human LOX-1 (hLOX-1). Upon overexpression in
HeLa cells also the human receptor underwent proteolysis
leading to the generation of NTFs (Fig. 9, A and B). Here, pri-
marily the smaller NTF2 was detected. We confirmed that NTF2
was efficiently cleaved in particular by coexpressed SPPL2b and
also processed by endogenous SPPL proteases (Fig. 9, C and D).
In this case, SPPL2a and SPPL2b shared a major cleavage site
C-terminal to M54 (Fig. 9, E–G). In addition, SPPL2b also cleaved
efficiently C-terminal to M58. SPPL2a and SPPL2b were ex-
pressed in human coronary artery endothelial cells (Fig. 9, H
and I) and could also be detected in foam as well as endothelial
cells in human atherosclerotic lesions by immunohistochem-
istry (Fig. 9 K). Therefore, we conclude that SPPL2a/b-mediated
LOX-1 processing according to the model depicted in Fig. 10 is
conserved in humans, strongly supporting a role of these pro-
teases in control of atherosclerosis beyond mice.
Discussion
Our findings identify proteolysis as a major regulatory mecha-
nism of the oxLDL receptor LOX-1. Two pathways, ectodomain
shedding and lysosomal degradation, generate LOX-1 NTFs,
which induce pro-atherogenic and -fibrotic signaling and re-
quire clearance by SPPL2a/b, representing a novel athero-
protective pathway. LOX-1 processing has previously gained
interest due to a soluble form of the receptor in plasma (Murase
et al., 2000). However, despite its association with vascular and
metabolic disorders (Pirillo and Catapano, 2013), its (patho-)
physiological function has remained elusive. Different studies
based on bovine aortic endothelial cells, macrophages, or HEK
cells have suggested serine proteases (Murase et al., 2000),
ADAM17 (Zhao et al., 2011), or ADAM10 (Mitsuoka et al., 2009)
to mediate this cleavage. Our data support a predominant
function of ADAM10 for liberation of sLOX-1 in HEK and also
murine endothelial cells.
In addition to ectodomain shedding, we have identified a so
far unknown lysosomal pathway of LOX-1 processing. Based on
NTF production, this lysosomal pathway exerts a significantly
higher contribution to LOX-1 turnover than ADAM10. Consti-
tutive internalization of LOX-1 has been observed before (Murphy
et al., 2008), but not linked to lysosomal proteolysis. Cellular
levels of several receptors are controlled by lysosomal deg-
radation, including the EGF receptor (Eden et al., 2009) and
many G protein–coupled receptors (Hanyaloglu and von
Zastrow, 2008). Usually this involves sorting into intralu-
minal vesicles by the Endosomal Sorting Complexes Re-
quired for Transport pathway (Babst and Odorizzi, 2013).
In contrast, LOX-1 processing by lysosomal proteases and
SPPL2a/b rather takes place in the limiting membrane of
such compartments, thereby releasing the LOX-1 ICD into the
cytosol (Fig. 2 A). Whether this cleavage fragment exerts
regulatory functions remains to be investigated.
The enhanced pro-atherogenic signaling upon SPPL2a/b in-
hibition or deficiency was phenocopied by overexpression of the
LOX-1 NTF, identifying the accumulation of this fragment as
underlying mechanism. The NTF-induced signaling was ligand-
independent and also observed in a cell type with no response to
oxLDL without overexpression of the full-length receptor. This
argues for an autonomous signaling by the LOX-1 NTF. This was
driven by MAP kinases, including ERK and p38, in contrast to
the ligand induced by the full-length receptor, which also acti-
vates NFκB (Cominacini et al., 2000; Matsunaga et al., 2003).
This supports a model of two different LOX-1 signaling modes.
With detectable levels of the NTF in aortae from WT mice
(Fig. 4 F) and its increase under atherogenic conditions (Fig. S2 A),
this novel mode of LOX-1 signaling is likely of pathophysiological
importance.
We showed that the TMD of the LOX-1 NTF is critical for its
ability to activate MAP kinases, but also for homophilic inter-
actions. Multimerization could be a prerequisite for recruitment
of cytosolic proteins or transmembrane signaling adaptors.
However, even unbiased immunoprecipitation in combination
withmass spectrometry (IP-MS) approaches have so far failed to
identify potential candidates. Thus, the direct molecular link
between the LOX-1 NTF and the activation of ERK and p38 re-
mains to be identified. Our inhibitor experiments indicated that
multiple pathways including MEK1/2, Src family kinases, and
ROCK1/2 are involved in this process, suggesting that different
protein interactions of the NTF are involved. Whereas an impact
of MEK1/2 inhibition on LOX-1 signaling has been described (Hu
et al., 2008b; Yang et al., 2017), a role of Src family kinases is a
and Sirius Red staining, respectively. Bars, 200 µm. N = 2, n = 13–18 (αSMA); n = 13–17 (MAC3), n = 15–18 (size), n = 15–19 (Sirius Red). (D) Quantification of
necrotic plaque area. N = 2, n = 16–18. (E) Scoring of atherosclerotic plaques. (F) Activation of ERK1/2 and p38 MAP kinases as well as ICAM-1 levels was
compared in atherosclerotic aortae fromWT and dKOmice. (G)Quantification of pERK/ERK (N = 2, n = 6), p-p38/p38 (N = 4, n = 11–12) and ICAM-1/actin (N = 2,
n = 5–6) ratios. As described in Materials and methods, phosphorylated and total forms of ERK and p38 were detected from the same membranes. After
detection of pERK and p38, the respective membranes were stripped and reprobed to detect the total proteins. Student’s t test. ***, P ≤ 0.001; **, P ≤ 0.01;
*, P ≤ 0.05; ns, not significant. N, the number of independent experiments; n, the number of individual samples for quantification. All data are shown as mean ± SD.
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novel observation; however they have been found to be up-
stream of MAP kinases in other contexts (Singer et al., 2011). As
delineated for oxLDL-induced signaling by full-length LOX-1
(Mattaliano et al., 2010), Rho-associated kinases contribute to
the pro-atherogenic signaling of the NTF. However, we failed to
detect an interaction between the LOX-1 NTF and ROCK-2 (data
not shown), which had been reported for full-length LOX-1
(Mattaliano et al., 2010). This indicates that the mechanism
activating this pathway differs between full-length LOX-1 and
the NTF. In general, links between the ROCK pathway and MAP
kinases have been observed (Schwartz, 2004; Zhao et al., 2012;
Cui et al., 2014).
Several of the identified LOX-1 NTF downstream targets
(Fig. 7 E) have been linked with LOX-1 before, including Cxcl2
(Mattaliano et al., 2009), Csf2 (Yang et al., 2017), Ctgf (Hu et al.,
2009), and Icam1 (Zhu et al., 2005). These genes cover a wide
range of biological functions including endothelial adhesion
molecules (Icam1), cytokines/chemokines (Cxcl2, Csf2), and
growth factors (Ctgf, Pdgfb). With regard to atherosclerosis, the
up-regulation of these targets triggers multiple axes promoting
leukocyte recruitment (Wolpe et al., 1989), immune cell and
smooth muscle cell proliferation (Biwa et al., 2000; Raines,
2004; Zhu et al., 2009), cell migration (Raines, 2004; Al-
Alwan et al., 2013), and extracellular matrix deposition (Fan
et al., 2000). In particular, the adhesion molecule ICAM-1
plays a critical role in atherosclerotic plaque development
(Kitagawa et al., 2002). CTGF is overexpressed in plaques and
enhances plaque fibrosis (Cicha et al., 2005). In sum, the effects
of increased LOX-NTF levels are not only pro-atherogenic but
also pro-fibrotic. This agrees well with a reduced collagen de-
position in atherosclerotic lesions of LOX-1−/− mice (Hu et al.,
2008a). Importantly, the pro-fibrotic activity of LOX-1 is not
limited to atherosclerosis, but has also been observed in other
disease models (Hu et al., 2009; Lu et al., 2012; Wang et al., 2012;
Dai et al., 2014; Deng et al., 2016). It will be of interest if also in
these contexts LOX-1 signaling is controlled by SPPL2a/b proteases.
Our findings further establish SPPL2a/b and I-CLIPs as reg-
ulators of membrane-associated signaling. This was previously
suggested by identifying the CD74 NTF, a substrate of SPPL2a
(Schneppenheim et al., 2013), as a negative regulator of B cell
receptor signaling (Hüttl et al., 2015). Further examples are the
receptor proteins TREM-2 (Wunderlich et al., 2013; Glebov et al.,
Figure 9. The role of SPPL2a/b for processing of LOX-1 NTFs is conserved in humans. (A) HeLa cells were transfected with HA-tagged hLOX-1 alone or in
combination with human SPPL2a (hSPPL2a) or SPPL2b (hSPPL2b-myc). Where indicated, cells were treated with 20 µM ZLL for 6 h before lysis and Western
blot analysis. (B) Quantification of A. N = 3–4, n = 3–4. One-way ANOVA with Dunnett’s post hoc test. (C) Accumulation of hLOX-1 NTFs in HeLa cells upon
inhibition of endogenous SPPL2 proteases with 10, 20, and 40 µM ZLL. (D) Quantification of C for 40 µM ZLL treatment. N = 4, n = 8. Student’s t test.
(E–G) The cleavage sites of human SPPL2a and SPPL2b in the TMD of hLOX-1 were analyzed by MS using V5-hLOX-1 NTF N73A-FLAG as model substrate.
Arrows indicate peptides up-regulated by protease overexpression (red, dominant peaks). Peak 4 corresponds to a peptide starting at Q59 with a potential
glutamate to pyroglutamate conversion. Rel., relative. (H and I) SPPL2a and SPPL2b are expressed in human coronary artery endothelial cells (HCAECs) as
revealed by RT-PCR (H) and qRT-PCR (I). (K) Presence of SPPL2a and SPPL2b in human atherosclerotic plaques was investigated by immunohistochemistry.
Bars, 400 µm; close-ups, 50 µm. ***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05; ns, not significant. N, the number of independent experiments; n, the number of
individual samples for quantification. All data are shown as mean ± SD.
Figure 10. The intramembrane proteases SPPL2a/b control the development of atherosclerosis. SPPL2a and SPPL2b maintain endothelial homeostasis
by clearing LOX-1 NTFs generated by ADAM10 and in lysosomes, thereby releasing the LOX-1 ICD. In the absence of SPPL2a/b, LOX-1 NTFs accumulate,
enhance oxLDL-induced signaling by full-length LOX-1, and activate MAP kinases in a ligand-independent manner. This promotes endothelial dysfunction and
causes a pro-atherogenic and pro-fibrotic phenotype in SPPL2a/b double-deficient mice when challenged with hypercholesterolemia.
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2016) and BCMA (Laurent et al., 2015), which are both substrates
of γ-secretase. Based on a broad repertoire of type II trans-
membrane receptors, it may be anticipated that regulation by
SPPL2a/b may not be limited to LOX-1.
While proteases like ADAM10 (van der Vorst et al., 2015),
ADAM17 (Nicolaou et al., 2017), and γ-secretase (Aoyama et al.,
2009) have been implicated in atherosclerosis, this is the first
report on the role of SPPL2a/b in this process. Due to poor
breeding efficacy of SPPL2a/b double-deficient mice, we applied
a novel atherosclerosis model based on overexpression of a gain-
of-function variant of murine PCSK9. This protein binds to LDL
receptor molecules to induce their lysosomal degradation,
thereby mimicking the genetic ablation of the LDL receptor
(Bjørklund et al., 2014). PCSK9-transduced mice show all hall-
marks of atherosclerosis upon administration of a Western-type
diet including hypercholesterolemia, aortic lesion formation,
plaque necrosis, and vessel calcification comparable to the more
established Ldlr−/− or Apoe−/− atherosclerosis models (Goettsch
et al., 2016; Jacobsen et al., 2017; Rogers et al., 2017; Theodorou
et al., 2017). This makes PCSK9 overexpression a valuable tool
for the study of atherosclerosis, especially where complex
breeding procedures involving multiple alleles would need to be
performed. Using this model, we demonstrate that SPPL2a/b
exert a relevant impact on atherosclerotic plaques development.
Most likely, the performed in vivo model underestimates the
role of these proteases. First of all, macrophages did not exhibit
SPPL2a/b deficiency in our model due to the bone marrow
transfer. Though their functionality may be modulated by other
substrates like CD74, additional blocking of LOX-1 proteolysis
in these cells may further promote atherosclerosis. In addi-
tion, the induction of hypercholesterolemia was less efficient
in dKO mice as compared with controls. It is quite remarkable
that these mice developed larger and more advanced plaques
despite 30% lower plasma cholesterol. Presumably, this differ-
ence would have been even more pronounced with comparable
hypercholesterolemia.
In general, the enhanced MAP kinase signaling, ICAM levels,
and fibrosis in plaques of the dKO mice correlate well with our
cell-based experiments, where LOX-1 NTF overexpression pheno-
copies SPPL2a/b inhibition. This strongly suggests impaired
LOX-1 proteolysis as the predominant mechanism underlying
the in vivo phenotype. However, a contribution of low-abundant
substrates that have evaded our proteomic analysis is difficult to
formally exclude.
Pharmacological inhibition of SPPL2a is currently investi-
gated as a therapeutic approach for immunosuppression based
on blocking CD74 cleavage in B cells and dendritic cells. Our
results strongly advocate the development of SPPL2a inhibitors,
which spare the activity of SPPL2b at least to a relevant degree.
Otherwise, they may increase the risk of atherosclerosis by
blocking LOX-1 proteolysis. Vice versa, any means of enhancing
SPPL2a/b-mediated proteolysis, which would deplete LOX-1 NTFs
and thereby abolish their pro-atherogenic effects, may be
beneficial to delay the progression of atherosclerosis. If SPPL2a
or SPPL2b expression could be induced pharmacologically, this




Generation of SPPL2a/b dKOmice has been described previously
(Schneppenheim et al., 2014b). All mice were backcrossed for 10
generations in a C57BL/6N Crl background. For all experiments,
WT mice with the same genetic background bred and housed in
the same animal facility were used as controls. Breeding of mice
has been approved by the Ministerium für Energiewende,
Landwirtschaft, Umwelt und ländliche Räume of Schleswig-
Holstein (V 242.7224.121–3), and animal care and handling
were performed in accordance with local and national guide-
lines. Mice were housed in individually ventilated cages in the
animal facility of the Christian-Albrechts-University Kiel, Kiel,
Germany. The atherosclerosis experiment was conducted with
ethical approval by the Animal Ethics Committee of Maastricht
University, Maastricht, Netherlands (permit number 2014–097).
Plasmids
Expression constructs encoding WT murine SPPL2a and SPPL2b
fused to a C-terminal myc epitope or their catalytically inactive
mutants D416A or D414A as well as corresponding constructs for
human SPPL2a were described before (Behnke et al., 2011;
Schneppenheim et al., 2013, 2014a,b). C-terminally myc-tagged
constructs encoding either WT or catalytically inactive (D421A)
human SPPL2b were derived from previously described cDNAs
(Fluhrer et al., 2006) and inserted into pcDNA3.1 Hygro+ vectors
(Thermo Fisher Scientific) using HindIII and XhoI restriction
sites. The open reading frame coding for murine LOX-1 was
amplified from a LOX-1 expression plasmid that was a kind
gift of Tatsuya Sawamura (National Cerebral and Cardiovas-
cular Center, Osaka, Japan). The PCR product comprising an
N-terminally appended HA epitope was ligated into pcDNA3.1
Hygro+ via BamHI and XbaI restriction sites. Based on this
plasmid, glycosylation mutants of the murine oxLDL receptor
were generated by mutating N72 and N92 to alanines. With the
exception of Fig. 9, where human LOX-1 (hLOX-1) and SPPL2a/b
(hSPPL2a, hSPPL2b) constructs were employed, in all other
experiments the murine cDNAs were used. A GFP-encoding
pMSCV puro plasmid was a kind gift of Michael Engelke
(University of Göttingen, Göttingen, Germany). Untagged murine
full-length LOX-1 or the putative murine LOX-1 NTF consisting
of amino acids 1–88 of the receptor was cloned into the pMSCV
puro vector (Clontech) using BglII and XhoI restriction sites.
Correspondingly, a HA-LOX-1-FLAG construct in this vector
was generated. A murine LOX-1 cDNA carrying an N-terminal
or C-terminal 3xFLAG-tag was ligated into pcDNA4.0 TO. The
coding sequence of hLOX-1 was obtained from Sinobiological,
fused to anN-terminal HA tag, and cloned into pcDNA3.1 Hygro(+)
via BamHI and XbaI restriction sites. For mass-spectrometric
determination of the SPPL2a/b cleavage sites in human and
murine LOX-1 NTFs, coding sequences of NTFs comprising
amino acids 1–88, with appended N-terminal V5- and C-terminal
FLAG epitopes, were inserted into pcDNA3.1 Hygro+. In these
constructs, the glycosylated asparagine residues N72 (murine)
and N73 (human) were mutated to alanine to reduce complexity
of mass spectrometric analysis. HA- or untagged TMD mutants
of murine LOX-1 (TMDstab, B1I, B2I, B3I, B3I) as well as the
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unphosphorylatable LOX-1 NTF mutant (T2A, S18A, SS30/31AA)
were cloned into the pMSCV puro vector using its BglII and XhoI
restriction sites.
Cell culture and transfection
HeLa cells (DSMZ), Flip-In T-REx 293 (Invitrogen), HEK293
ADAM10/17 KO cells, MEFs, and Platinum-E retroviral packaging
cells (Cell Biolabs, Inc.) were cultivated in DMEM (GIBCO) sup-
plementedwith 10% FCS (Biochrom) aswell as 100U/ml penicillin
(Sigma-Aldrich) and 100 µg/ml streptomycin (Sigma-Aldrich).
ADAM10 and ADAM17 single- and double-deficient HEK293 cells
were generated by CRISPR/Cas9 genome editing and initially
described in Riethmueller et al. (2016). iMAECs were a kind gift
of Prof. Hanjoong Jo (Emory University, Atlanta, GA) and cul-
tured as described in Bond et al. (2010).
MEFs were isolated from 13.5-d-old embryos from WT,
SPPL2a−/−, SPPL2b−/−, and SPPL2a/b double-deficient mice. After
removing the head and internal organs, embryos were cut into
small pieces and incubated in Trypsin-EDTA for 15 min at 37°C.
The resulting tissue pieces were dissociated by pipetting and the
cell suspension transferred to 12 ml prewarmed DMEM sup-
plemented with 10% FCS and antibiotics. Cells were sedimented,
washed once in fresh medium, and plated out for culture. For
immortalisation, MEFswere transfected at an early passage with
an expression plasmid of the SV40 large T antigen (pMSSVLT;
Schuermann, 1990). After an average of 10 passages, immor-
talized cells were used for experiments.
Bone marrow–derived dendritic cells (BMDCs) were generated
as described in Schneppenheim et al. (2014b) based on the pro-
tocol published by Lutz et al. (1999). For detection of N-terminal
fragments of TNF, BMDCs were activated for 6 h with 500 ng/ml
lipopolysaccharides from Escherichia coli (Sigma-Aldrich).
For transient transfection of HeLa, iMAEC, MEF, and
Platinum-E cells, Turbofect transfection reagent (Thermo Fisher
Scientific) was applied. Flip-In T-REx 293 cells stably expressing
murine LOX-1 were generated by transfection with the respec-
tive construct and the pOG44 vector encoding the Flp re-
combinase followed by selection with 100 µg/ml hygromycin
and 10 µg/ml blasticidin (both Invivogen). After selection, sur-
viving clones were combined and further analyzed as polyclonal
cell lines. To induce transgene expression, 10 µg/ml doxycycline
(Sigma-Aldrich) was added to the medium for 24 h. To ensure
homogenous expression of the LOX-1 NTF in transiently trans-
fected HEK293 cells, when analysis of signaling pathways was
intended, cells were transfected in 6-cm cell culture dishes with
2 µg of either a LOX-1 NTF coding construct or a corresponding
empty vector harboring a puromycin resistance cassette (pMSCV).
1 d after transfection, fresh medium containing 10 µg/ml
puromycin was added, and cells were incubated for 4 d be-
fore further processing for Western blot analysis.
In LOX-1–expressing cell lines, LOX-1–dependent signal
transduction was stimulated with 40 µg/ml oxLDL obtained
from Hycultec. To influence proteolytic processing of LOX-1,
several compounds were added, if not indicated differently, 24 h
before analysis to the medium of cultured cells. The lysosomal
acidification inhibitor bafilomycin a1 (Sigma-Aldrich) was used
in a final concentration of 100 nM. To inhibit cysteine and serine
proteases, E-64d (40 µM; Enzo), Leupeptin (2.5 µM; Roth), and
AEBSF (500 µM; Sigma-Aldrich) were applied. The cell-
permeable Pepstatin A–methyl ester (10 µM; Merck) was used
to interfere with the activity of aspartyl proteases. Activity of
the metalloproteinases ADAM10 and ADAM17 was blocked by
marimastat (10 µM; Sigma-Aldrich) or stimulated by treatment
with ionomycin (1 µM; Sigma-Aldrich) or PMA (100 nM; Sigma-
Aldrich), respectively. SPPL2 proteases were inhibited by applica-
tion of the SPP family inhibitor ZLL (Peptanova) in concentrations
ranging from 10 to 40 µM. For kinase inhibition, the MEK1/2-
inhibitor U0126 (25 µM; Sigma-Aldrich), the Src-family inhibitor
Saracatinib (1 µM; Selleckchem), or the ROCK inhibitor Y-27632
(10 µM; Cayman Chemicals) was applied. To allow for detection
of CTGF in lysates of empty vector or LOX-1 NTF–expressing
iMAECs, Brefeldin A (Sigma-Aldrich) was applied in a concen-
tration of 1 µg/ml to the culture medium for 6 h before lysis of
the cells. Except for Leupeptin, E64-d, and Y-27632, which were
applied as aqueous solutions, all small molecule inhibitors were
dissolved in DMSO, which was used as solvent control in re-
spective experiments.
Retroviral transduction
For generation of ecotropic retroviruses for transduction of
iMAEC and MEF cells, Platinum-E cells were transfected using
Turbofect transfection reagent. After 48 h, virus-containing
supernatants were removed from Platinum-E cultures and
passed through a 20-µm filter (BD Biosciences). Subsequently,
supernatants supplemented with 8 µg/ml polybrene (Sigma-
Aldrich) were added to the respective cells seeded a day before
in 10-cm culture dishes. 1 d after transduction, supernatants
were replaced by fresh culture medium containing 10 µg/ml
puromycin (Invivogen). Stably transduced cells were main-
tained as polyclonal cell lines without subcloning.
Protein extraction and Western blot analysis
Cell and tissue lysis was performed as described in Schneppenheim
et al. (2013). In brief, cells were harvested by centrifugation
and subsequently extracted in lysis buffer (50 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 1.0% Triton X-100, and 0.1% SDS) supple-
mented with Complete protease inhibitor mix (Roche), 0.5 µg/ml
Pepstatin A (Sigma-Aldrich), 4 mM EDTA, and 4 mM Pefabloc SC
Protease Inhibitor (Roth). Aortic vessels were flushed with PBS
and cleaned from adherent adipose and connective tissue. For
lysis, 150 µl of lysis buffer and ceramic beads was added to each
aorta, whichwas homogenized by vigorous shaking of themixture
in a Precellys homogenizer (Peqlab). Afterward, cell and tissue
suspensions were sonicated using a Branson Sonifier 450 (Emer-
son Industrial Automation) and incubated at 4°C for 1 h. The
remaining debris was pelleted by centrifugation at 13,000 g
for 10 min at 4°C, and protein concentrations of supernatants
were determined using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). After lysis, protein lysates were comple-
mented with the required amount of reducing SDS-PAGE
sample buffer according to Laemmli (1970) and denatured for
10 min at 56°C.
For recovery of sLOX-1 from conditionedmedia of HA-LOX-1-
FLAG or mLOX-1-3xFLAG expressing iMAEC or HEK293 cells,
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these were cultured in serum free medium for 30 min before
stimulation with ionomycin or PMA for 30 min. After stimula-
tion, 800 µl supernatant was supplemented with 200 µl 100%
(wt/vol) TCA for 1 h at 4°C. Precipitated proteins were sedi-
mented by centrifugation at 13,000 g for 10 min at 4°C. The
resulting pellet was washed once with ice-cold acetone before
resuspension in reducing SDS-PAGE sample buffer and dena-
turation at 95°C for 10 min.
Electrophoretic separation by SDS-PAGE with a standard
Tris-glycine buffer system (Laemmli, 1970), semidry transfer to
nitrocellulose membranes, and immunodetection were con-
ducted as described previously (Schröder et al., 2010). Mono-
clonal antibodies against HA (3F10), myc (9B11), V5, and FLAG
(M2) epitope tags were obtained from Roche, Cell Signaling, or
Sigma-Aldrich, respectively. sLOX-1 was detected applying a
polyclonal goat antibody directed against the C terminus of this
protein (AF1564; R&D Systems). To allow detection of LOX-1
NTFs, rabbits were immunized with a synthetic peptide corre-
sponding to the amino acids 2–19 of the protein (Pineda Anti-
körper Service). Similarly, a polyclonal antiserum against
residues 575–592 of human SPPL2b was raised. In both cases,
antisera were affinity-purified against the immobilized immu-
nogens before use. Polyclonal antibodies for detection of murine
SPPL2a (Behnke et al., 2011), murine SPPL2b (Schneppenheim
et al., 2014b), and human SPPL2a (Schneppenheim et al., 2014a)
were described before. The polyclonal anti-TNF antibody has
been described earlier (Mentrup et al., 2015). Murine CD74 was
detected using the In-1 antibody directed against the N terminus
of the protein (BD Biosciences). For analysis of signaling path-
ways, monoclonal antibodies against the phosphorylated forms
of ERK1/2 (T202/Y204, D13.14.4E), p38 (T180/182, 3D7), p65
(S536, 93H1), and Akt (S473, D9E) as well as total ERK1/2 (137F5),
p38 (D13E1), p65 (C22B4), and Akt (C67E7) from Cell Signaling
were used. Phosphorylated and total forms of these kinases and
signaling factors were detected from the same membranes.
Therefore, immunodetection of the phosphorylated form was
performed first. Subsequently, bound antibodies were removed
from the membrane by incubation in 100 mM glycine-HCl,
20 mM magnesium acetate, and 50 mM KCl, pH 2.2, for 45 min
at 60°C. Membranes were washed several times in 25 mM Tris-
HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl, and 0.1% (vol/vol)
Tween-20 (TBS-T), and unspecific binding sites were reblocked
for at least 15 min in 5% (wt/vol) dry skim milk powder in
TBS-T. Then, primary antibodies against the total forms of the
respective kinases were applied, starting a second round of
immunodetection for providing a suitable loading control
from the same membrane. Murine ICAM-1 was detected with
the monoclonal antibody YN1/1.7.4 from BioLegend. CTGF was
detected with the polyclonal E-5 antibody from Santa Cruz
Biotechnology. Primary antibodies were diluted in 5% milk
powder (Roth) dissolved in TBS-T. For detection of phos-
phorylated proteins, 5% BSA (wt/vol; Roth) in TBS-T was used
as antibody diluent. Horseradish peroxidase–conjugated sec-
ondary antibodies were purchased from Dianova. Detection of
chemiluminescent signals was performed with a LAS4000
imaging system (GE Healthcare) and quantified densitometri-
cally using ImageJ.
Cross-link
HeLa cells were seeded in 6-cm dishes and transfected on the
following day as described before. On the next day, cross-linking
was performed using bis(sulfosuccinimidyl)suberate (BS3;
Thermo Fisher Scientific) as described in Matsunaga et al.
(2007) with slight modifications. In brief, cells were washed
three times with ice-cold PBS and incubated with 1 mM BS3 in
PBS or with PBS alone for 30 min on ice. Next, the cross-linking
medium was removed and the remaining BS3 was quenched in
20 mM Tris-HCl, pH 7.4, in PBS for 15 min on ice. Finally, cells
were scraped off in 500 µl PBS complemented with Complete
Protease inhibitor mix and processed for Western blot analysis
as described above.
oxLDL uptake assays
40,000 iMAECs per well were seeded in black 96-well plates
and preincubated for 4 h with either DMSO as control, 100 nM
bafilomycin a1, or 10 µM marimastat. Afterwards, cells were
treated with 10 µg/ml DiI-oxLDL (Thermo Fisher Scientific)
for 4 h, washed three times with prewarmed PBS, and ana-
lyzed for DiI-fluorescence in a SynergyHTmulti-detection reader
(BioTek).
Immunoprecipitation (IP)
Cell lysates were prepared in IP buffer (50 mM Tris-HCl,
150 mM NaCl, 1% (wt/vol) Triton X-100, and 4 mM EDTA)
supplemented with the same proteinase inhibitors as the stan-
dard cell lysis buffer described above. Incubation with primary
antibodies was performed at 4°C overnight under continuous
end-over-end rotation. The following day, 50 µl equilibrated
Protein G Agarose beads (Thermo Scientific) were added and the
incubation continued for 1 h. Beads were recovered by centrif-
ugation, washed five times with IP buffer, and finally eluted by
boiling in reducing SDS-PAGE sample buffer.
Indirect immunofluorescence
Immunocytochemical stainings were performed as described
previously (Schröder et al., 2010). Cells grown on coverslips
were fixed with 4% (wt/vol) paraformaldehyde. Lysosomal
compartments were visualized with the 2D5 monoclonal LAMP-2
antibody (Radons et al., 1992). Alexa 488- and 594-conjugated
secondary antibodies were purchased from Molecular Probes.
Nuclei were stained with DAPI (Sigma-Aldrich), which was
included in the embedding medium at a concentration of 1 µg/ml.
Images were acquired with an Olympus FV1000 confocal laser
scanning microscope and further processed with Olympus
Fluoview software and Adobe Photoshop software.
Flow cytometry
FACS analysis of stably transfected, inhibitor- or TNF (Im-
munotools)-treated iMAECs was facilitated by an antibody
against murine ICAM-1 (YN1/1.7.4) conjugated to the fluorophore
APC. For determination of surface LOX-1 levels in receptor
overexpressing iMAECs, LOX-1 was first marked with the
AF-1564 antibody (R&D Systems) before labeling of the primary
antibody with an anti-goat–Alexa 647 conjugate (Molecular
Probes). After detachment with Accutase (eBioscience) for
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5 min, cells were washed once in FACS buffer (PBS + 2% FCS +
2 mM EDTA) and subsequently stained with the indicated
antibodies for 1 h at 4°C. After subsequent additional staining
with propidium iodide (BD Biosciences), cells were resuspended
in 200 µl FACS buffer and analyzed using a FACS Canto flow
cytometer (BD Biosciences) and the FACSDiva software (BD Bio-
sciences). Further data processingwas performedwith the FlowJo
Software (Tree Star).
To assess the reconstitution of B cell development after bone
marrow transplantation in the atherosclerosis experiment, cell
suspensions were prepared from harvested spleens by passing
the tissue through a 70-µm cell strainer (Greiner). Splenocytes
were incubated in erythrocyte lysis buffer (150 mM NH4Cl and
10 mM NaHCO3, pH 7.4) for 2 min on ice, washed, and filtered
through a 70-µm cell strainer. Subsequently, splenic cells were
blocked with anti-CD16/32 (clone 93; eBioscience), washed,
and stained with antibodies against B220 (RA3-6B2; PE-Cy7;
eBioscience), CD21 (8D9; PE; eBioscience), and CD24 (30-F1;
APC; eBioscience). Cells were analyzed using a FACS Canto II
flow cytometer (BD Biosciences) and FACSDiva software v6 (BD
Biosciences) for data interpretation.
For quantification of LOX-1 internalization, iMAECs stably
overexpressing LOX-1 were incubated for 30 min on ice with an
antibody against the C terminus of the protein in the presence of
10 µMmarimastat or DMSO as control. Cells were washed twice
with ice-cold PBS and subsequently chased for 2 h at 37°C. After
detachment of the cells from the culture dishes, remaining
surface LOX-1 was labeled with an anti-goat–Alexa 647 antibody
and detected using a FACS Canto cytometer as described above.
Cleavage site determination
Epitope-tagged LOX-1 NTFs (V5-LOX-1-NTF-N72A-FLAG, V5-
hLOX-1-NTF-N73A-FLAG) were transiently expressed in T-REx
293 cells with or without stable overexpression of SPPL2a or
SPPL2b. The C-peptides released by the SPPL2-mediated intra-
membrane cleavage were recovered from conditioned media
using anti-FLAG M2-conjugated agarose beads (Sigma-Aldrich).
After repeated washing with IP-MS buffer (0.1% n-octyl gluco-
side, 10 mM Tris/HCl, pH 8.0, 5 mM EDTA, and 140 mM NaCl)
and sterile water, peptides were eluted using a trifluoroacetic
acid/acetonitrile/water mixture (1:20:20, vol/vol/vol) saturated
with α-cyano-4-hydroxycinnamic acid. The dissolved samples
were dried on a stainless plate and subjected to Matrix-assisted
laser desorption ionization–time of flight (MALDI-TOF)-MS
analysis using a VoyagerDE STR instrument (Applied Biosystems).
Proteomic analysis of murine aorta
The total proteome of three biologically independent aortic
samples from WT and SPPL2a/b-deficient mice was analyzed
and quantitatively compared. Each sample was prepared from
pooled aortae of two age- and sex-matched mice of the re-
spective genotype, which were extracted in 150 µl lysis buffer.
Lysate corresponding to 150 µg protein was mixed with 100 µl
30% acrylamide, 1.25 µl TEMED (N,N,N9,N9-tetramethylene-
thylendiamine) and 5 µl of 10% ammonium persulfate to trap
proteins in a gel matrix, fixed (50% methanol and 10% acetic
acid), washed with water, and cut into pieces. After dehydration,
proteins were reduced with 10 mM dithiothreitol at 60°C for
30min and alkylated using 55mM iodoacetamide. Subsequently,
proteins were digested by adding 200 µl of trypsin solution
(10 ng/µl) in 50 mM ammonium bicarbonate (Shevchenko et al.,
2006). After extraction using 10% formic acid and 50% and
100% acetonitrile, peptides were purified using the C18 SepPak
column system (Waters) and lyophilized.
Peptides were then labeled using TMT 6plex (Thermo Fisher
Scientific) according to the manufacturer. Samples were named
WT pool #1 (TMT126), WT pool #2 (TMT128), WT pool #3
(TMT130), dKO pool #1 (TMT127), dKO pool #2 (TMT129), and
dKO pool #3 (TMT131) and purified using the C18 SepPak column
system. Then, peptides were combined and fractionated by high
pH reversed-phase chromatography on a Phenomenex Gemini
3u C18 110A 250 × 3 mm column using a Dionex Ultimate 3000
HPLC as described (Treitz et al., 2015), reconstituted in 20 µl 5%
formic acid and submitted to liquid chromatography–tandem
MS analysis, which was performed using a Dionex U3000
nanoUHPLC coupled to a Q Exactive Plus mass spectrometer
(both from Thermo Scientific). 8 µl of each fraction was loaded
on a trap column (10 mm × 300 µm; 3 µm; 100 Å; Acclaim
Pepmap 100 C18; Dionex), and separation was performed using
an Acclaim PepMap 100 C18 analytical column (50 cm × 75 µm;
2 µm; 100 Å; Dionex) with a flow-rate of 300 nl/min using a
180-min gradient. MS data were acquired from 5 to 145minwith
MS full scans between 300 and 1,800 (m/z) at a resolution of
70,000 at m/z 200. The 15 most intense precursors were sub-
jected to high-energy collisional fragmentation. MS data were
searched using the SequestHT algorithm in Proteome Discoverer
2.2 (Thermo Scientific) against the entire reviewed Ensembl
protein database of Mus musculus (v. 6.7.2017) with full enzyme
specificity. Static modifications were carbamidomethylation on
cysteine residues, TMT on lysines and peptide N termini, while
oxidation of methionine residues was set as dynamic modifica-
tion. Two missed cleavages were allowed. Search tolerances
were set to 10 ppm for MS and 0.02 Dalton for MS/MS. The
protein group identifications were further filtered based on a
false discovery rate (FDR) confidence ≤ 0.01. TMT reporter ion
ratio quantification (Proteome Discoverer 2.2) was reported for
three independent biological replicates (WT/dKO). Reporter ion
abundances for the six channels were used to perform a two-
tailed t test, and analysis of the local FDR showed that a t test P
value of 0.04 corresponded to a FDR of 5%, hereby determining
our significance cut-off for reproducibility of differential protein
abundance. Boundaries for differential abundances betweenWT
and dKOwere set to statistically significant fold changes of more
than 1.4 (Table S2).
RT-PCR and quantitative gene expression analysis
Total cellular RNA was isolated with the NucleospinRNA Kit
(Macherey Nagel) according to the manufacturer’s recom-
mendations. Subsequently, RNA was transcribed into cDNA
using the RevertAid First Strand cDNA Synthesis Kit (Thermo
Scientific). RT-PCR analysis of human SPPL2 protease expres-
sion was performedwith the following primers: hSPPL2a-RT-fw:
59-AGTTGCCCAACTTCAAGTCATG-39, hSPPL2a-RT-rv: 59-CCA
AATGGTCCATCATCTGATAG-39, hSPPL2b-RT-fw: 59-ATCTTC
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ACGCGTTTCGGCCGCA-39, hSPPL2b-RT-rv: 59-CCAGGCCCACTG
GTCCTCGTTG-39, hGAPDH-RT-fw: 59-AGGTCGGAGTCAACGGAT
TTG-39, hGAPDH-RT-rv: 59-GTGATGGCATGGACTGTGGT-39. To
analyze potential differences in the expression of atherosclerosis-
related genes due to overexpression of the putative LOX-1 NTF,
mouse endothelial cell biology and mouse atherosclerosis RT2
Profiler PCR arrays (Qiagen) were employed using 500 ng of
total RNA isolates obtained from two independently generated
iMAEC lines stably transduced either with an untagged LOX-1 1–88
(NTF) coding construct or a corresponding empty vector control.
Arrays were performed in a 384-well format according to the
manufacturer’s recommendations. dCt-values were compared
between the four lines, and candidate genes were selected based
on an increased or decreased mean NTF/empty vector ratio and
low variability between the individual lines per construct. Genes
with highly different expression in equally transduced lines
were excluded for further follow-up.
For quantitative PCR (qPCR), 0.5 µl cDNAwas analyzed using
the Universal Probe Library System (Roche) and a Light Cycler
480II (Roche) as described in Mentrup et al. (2015). The fol-
lowing primers were used: mCtgf (probe 71) fw: 59-TGACCTGGA
GGAAAACATTAAGA-39; mCtgf (probe 71) rev: 59-AGCCCTGTA
TGTCTTCACACTG-39; mIcam1 fw (probe 64): 59-GCTACCATC
ACCGTGTACTTCG-39, mIcam1 rev (probe 64): 59-TGAGGTCCT
TGCCTACTTGC-39; mPdgfb fw (probe 74): 59-CGAGGGAGGAGG
AGCCTA-39, mPdgfb rev (probe 74): 59-GTCTTGCACTCGGCG
ATTA-39; mCxcl2 fw (probe 26): 59-AAAATCATCCAAAAGATA
CTGAACAA-39, mCxcl2 rev (probe 26): 59-CTTTGGTTCTTCCGT
TGAGG-39; mCcl5 fw (probe 110): 59-TGCAGAGGACTCTGAGAC
AGC-39, mCcl5 rev (probe 110): 59-GAGTGGTGTCCGAGCCATA-
39; mKdr fw (probe 18): 59-CCCCAAATTCCATTATGACAA-39,
mKdr rev (probe 18): 59-CGGCTCTTTCGCTTACTGTT-39;
mPdgrfb fw (probe 67): 59-TCAAGCTGCAGGTCAATGTC-39,
mPdgrfb rev (probe 67): 59-CCATTGGCAGGGTGACTC-39; mPf4
fw (probe 64): 59-TCTGGGATCCATCTTAAGCAC-39, mPf4 rev
(probe 64): 59-CCATTCTTCAGGGTGGCTAT-39; mCsf2 fw (probe
79): 59-GCATGTAGAGGCCATCAAAGA-39, mCsf2 rev (probe 79):
59-CGGGTCTGCACACATGTTA-39; mFgf1 fw (probe 41): 59-CAG
CCTGCCAGTTCTTCAG-39, mFgf1 rev (probe 41): 59-GGCTGC
GAAGGTTGTGAT-39; mCol3a1 fw (probe 49): 59-TCCCCTGGA
ATCTGTGAATC-39, mCol3a1 rev (probe 49): 59-TGAGTCGAA
TTGGGGAGAAT-39; mCflar fw (probe 51): 59-GCAGAAGCTCTC
CCAGCA-39, mCflar rev (probe 51): 59-TTTGTCCATGAGTTCAAC
GTG-39. Expression of individual genes was normalized to that
of Tuba1a, which was detected using the following primers:
mTuba1a fw (probe 88): 59-CTGGAACCCACGGTCATC-39; mTuba1a
rev (probe 88): 59-TGTAGTGGCCACGAGCATAG-39.
Bone marrow transplantation and atherosclerosis model
1 wk before bone marrow transplantation, female WT and
SPPL2a/b dKO mice received water supplemented with anti-
biotics (neomycin, 100 mg/liter, and Polymyxin B sulfate,
60,000 U/liter, both from Gibco), which was continued for
5 wk after the procedure. Mice were exposed to 6 Gy total
body irradiation 1 d before and on the day of transplantation
with 5 × 106 bone marrow cells isolated from WT mice. After a
recovery period of 5 wk, hypercholesterolemia was induced by
adeno-associated viral expression of a gain-of-function mutant
of PCSK9 (rAAV8-D377Y-mPCSK9) according to Bjørklund et al.
(2014). Viral particles produced by the University of North
Carolina Vector Core were injected into the tail vein of the mice
(1011 genome copies). Concurrently, mice were fed an HCD
containing 0.25% cholesterol in addition to 15% cacao butter,
1% corn oil, 40.5% sucrose, 10% corn starch, and 5.95% cellu-
lose (824171; Special Diets Services) for 9 wk. Plasma con-
centrations of triglycerides and cholesterol were determined
at baseline just before HCD initiation as well as after 9 wk
using standard enzymatic kits (Cholesterol FS910; Trigly-
cerides FS 59 Ecoline; Diagnostic Systems GmbH) according to
the manufacturer’s instructions. Prior to blood sampling from
the tail vein, mice were fasted for 4 h.
Female LDL receptor–deficient (Ldlr−/−) mice (n = 4, C57Bl6
background) were obtained from in-house breeding, irradiated
2× with 6 Gy, and reconstituted withWT bonemarrow, followed
by HCD (824171; Special Diets Services) feeding for 3 wk (permit
number 2014–019; Maastricht University, Netherlands).
Histological analysis
After 9 wk of HCD feeding, mice were anesthetized, euthanized,
and perfused with PBS containing nitroprusside (0.1 mg/ml;
Sigma-Aldrich). Hearts were excized and fixed in 1% parafor-
maldehyde overnight. Serial paraffin sections of the aortic root
were cut (4 µm) and stained with H&E (Sigma-Aldrich) for
morphometric analysis of plaque size and necrotic core area
(defined as acellular region). Total plaque areas per mouse were
obtained by averaging measurements of five consecutive H&E-
stained sections (4 µm, 20 µm apart) at the same anatomical
location in the aortic root, starting at the first appearance of the
medial layer. Plaque stages were determined as previously de-
scribed (Gijbels et al., 1999), with slight modifications. Plaques
were classified as early (foam cell–rich but lacking a necrotic
core), moderately advanced (containing a fibrotic cap and often a
necrotic core, but no medial macrophage infiltration), and ad-
vanced lesions (typified bymedial macrophage infiltrates, elastic
lamina degradation, andmore pronounced necrosis andfibrosis).
Atherosclerotic lesions were further analyzed for abundance
of macrophages (1:200; MAC3; clone M3/84; BD Biosciences),
smooth muscle cells (1:3,000; αSMA; clone 1A4; Sigma-Aldrich)
and collagen content (Sirius Red; Polysciences). Sections (MAC3,
αSMA) were subjected to heat-induced antigen retrieval using
citrate buffer (pH 6; DAKO), and specific antigen-antibody
binding was visualized using appropriate biotinylated secondary
antibodies, ABC horseradish peroxidase (Vector Laboratories),
and DAB substrate kit (DAKO). Cell nuclei were counterstained
with hematoxylin. Pictures were taken using a Leica DM3000
light microscope, and sections were analyzed in a blinded
manner using Adobe Photoshop CS6 software.
Immunohistochemistry of human plaque sections
Collection, storage, and use of human carotid artery tissue in the
Maastricht Pathology Tissue Collection and patient data confi-
dentiality were performed after informed consent and in
agreement with the “Code for Proper Secondary Use of Human
Tissue in the Netherlands,” which is in accordance with the
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guidelines of and approved by themedical and ethical committee
of Maastricht University Medical Centre, Maastricht, Nether-
lands. Human carotid endarterectomy segments were fixed in
paraformaldehyde and paraffin-embedded. Sections were incu-
bated with polyclonal antisera against human SPPL2a or SPPL2b
(described above), followed by detection with Brightvision sec-
ondary antibodies (Immunologic) and Vector Red (Vector Lab-
oratories). Cell nuclei were counterstained with hematoxylin.
Pictures were taken using a Leica DM3000 light microscope.
Statistical analysis
For statistical analysis, an unpaired Student’s t test or a one-way
ANOVA with either Tukey’s or Dunnett’s post hoc testing was
performed as indicated in the individual figure legends using
GraphPad Prism. All data are shown as mean ± SD. Where stably
transduced iMAECs were used, data quantification is based on at
least three independently generated cell lines. N describes the
number of independent experiments, and n depicts the number
of individual samples for quantification.
Online supplemental material
Fig. S1 summarizes supporting data from the analysis of LOX-1
NTF generation and the mass-spectrometric cleavage site de-
terminantion. Fig. S2 depicts the increase of Lox-1 NTFs upon
induction of atherosclerosis as well as the reconstitution of
the B cell defect of SPPL2a/b-deficient mice by bone marrow
transplantation. In Fig. S3, data addressing the potential in-
volvement of other SPPL2a/b substrates are shown. Table S1
shows the full dataset obtained from the performed mouse
endothelial cell biology and mouse atherosclerosis RT2 Profiler
PCR arrays. In Table S2, all proteins identified in the compar-
ative proteomic analysis of WT and SPPL2a/b-deficient aortae
are listed.
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Kröper for excellent technical assistance. We are grateful to
Tatsuya Sawamura (National Cerebral and Cardiovascular
Center, Osaka, Japan), Michael Engelke (University of Göttingen,
Göttingen, Germany), and Hanjoong Jo (Emory University,
Atlanta, GA) for plasmids and cell lines. We thank Kristiaan
Wouters (Maastricht University, Maastricht, Netherlands) for
providing material from LDL receptor–deficient mice. We are
also grateful for support by the Z3 imaging unit of the SFB877.
This work was supported by the Deutsche Forschung-
sgemeinschaft as part of the SFB877 (project B7 to B. Schröder,
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